贝利尤单抗在狼疮肾炎中的应用  

Application of Belizumab in Lupus Nephritis

作　　者：孔寒 梅峰[2] 

机构地区：[1]青海大学临床医学院,青海 西宁 [2]青海大学附属医院肾病科,青海 西宁

出　　处：《临床医学进展》2023年第5期8421-8430,共10页Advances in Clinical Medicine

摘　　要：近十年来,狼疮性肾炎的发病率和患病率逐渐升高,使活动性狼疮肾炎患者达到肾脏完全缓解显得尤为重要。激素联合免疫抑制剂的治疗方案虽然可以达到较好的临床疗效,但长期应用激素所带来的不良反应也不少。而靶向B细胞治疗为狼疮性肾炎的治疗提供了新的方向,贝利尤单抗可以通过抑制B细胞活化因子来耗竭异常B细胞,从而达到治疗活动性狼疮肾炎的目的。国外已有大量临床数据可以表明贝利尤单抗的临床疗效和安全性。这种新型的治疗方案为改善自身免疫性肾病的患者的生活质量提供了可能,靶向B细胞治疗还包括许多其他的治疗,需要我们进一步了解研究。The incidence and prevalence of lupus nephritis have gradually increased in the last decade, and it is particularly important to enable patients with active lupus nephritis to achieve complete renal remission. Although hormone combined with immunosuppressive regimens can achieve better clinical efficacy, there are many adverse effects associated with long-term hormone application. Targeted B-cell therapy provides a new direction for the treatment of lupus nephritis. Belimumab can deplete abnormal B-cells by inhibiting B-cell activating factors, thus achieving the goal of treat-ing active lupus nephritis. A large amount of clinical data from abroad can demonstrate the clinical efficacy and safety of Belimumab. This novel treatment option offers the possibility to improve the quality of life of patients with autoimmune nephropathy. Targeted B-cell therapy also includes many other treatments that need to be further investigated for our understanding.

关 键 词：贝利尤单抗 狼疮肾炎 系统性红斑狼疮 

分 类 号：R59[医药卫生—内科学]